Toripalimab-tpzi: the monoclonalantibodies approved by fda this year
Toripalimab-tpzi is another of the #monoclonalantibodies approved by #fda this year, to treat recurrent or #metastatic nasopharyngeal #carcinoma when used together with or following other therapies* It is expressed in a recombinant Chinese Hamster Ovary (#CHO) mammalian cell expression system, reminding again, if still needed, the importance of CHO cells in producing the #drugs of today and tomorrow and demonstrating the intense activity of research and […]